PDCD1 and melanoma: Matson et al showed that, in melanoma patients who were administrated with PD‐1 antibody, responders had more abundant fecal bacterial species than non‐responders, and germ‐free mice transplanted with fecal bacteria from responding patients showed activated immune response and improved efficacy of anti‐PD‐L1 therapy.7